The Lancet | Biosimilar adalimumab for patients with active rheumatoid arthritis @TheLancetTV | Uploaded August 2023 | Updated October 2024, 7 minutes ago.
Dr. Roy Fleischmann from the University of Texas Southwestern Medical Center in Dallas, Texas, presents a study of multiple switches between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis.

The study was published in The Lancet Rheumatology in August 2023.
Read the full paper here: thelancet.com/journals/lanrhe/article/PIIS2665-9913(23)00161-3/fulltext?dgcid=youtube_video_tlrheu

Visit The Lancet Rheumatology at thelancet.com/journals/lanrhe/home?dgcid=youtube_video_tlrheu
Find out more at thelancet.com/?dgcid=youtube_video_lancet_lancet

* * *
Continue this conversation on social! Follow us today at…
twitter.com/TheLancet
facebook.com/TheLancetMedicalJournal
instagram.com/thelancetgroup
linkedIn.com/company/the-lancet